Literature DB >> 19969453

Optimization of piperidyl-ureas as inhibitors of soluble epoxide hydrolase.

Anne B Eldrup1, Fariba Soleymanzadeh, Neil A Farrow, Alison Kukulka, Stéphane De Lombaert.   

Abstract

Inhibition of sEH is hypothesized to lead to an increase in epoxyeicosatrienoic acids resulting in the potentiation of their anti-inflammatory and vasodilatory effects. In an effort to explore sEH inhibition as an avenue for the development of vasodilatory and cardio- or renal-protective agents, a lead identified through high-throughput screening was optimized, guided by the determination of a solid state co-structure with sEH. Replacement of potential toxicophores was followed by optimization of cell-based potency and ADME properties to provide a new class of functionally potent sEH inhibitors with attractive in vitro metabolic profiles and high and sustained plasma exposures after oral administration in the rat. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19969453     DOI: 10.1016/j.bmcl.2009.11.091

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  9 in total

1.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

2.  Exploring conformational search protocols for ligand-based virtual screening and 3-D QSAR modeling.

Authors:  Daniel Cappel; Steven L Dixon; Woody Sherman; Jianxin Duan
Journal:  J Comput Aided Mol Des       Date:  2014-11-19       Impact factor: 3.686

3.  A self-compartmentalizing hexamer serine protease from Pyrococcus horikoshii: substrate selection achieved through multimerization.

Authors:  Dóra K Menyhárd; Anna Kiss-Szemán; Éva Tichy-Rács; Balázs Hornung; Krisztina Rádi; Zoltán Szeltner; Klarissza Domokos; Ilona Szamosi; Gábor Náray-Szabó; László Polgár; Veronika Harmat
Journal:  J Biol Chem       Date:  2013-04-30       Impact factor: 5.157

4.  Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.

Authors:  Leila Karami; Ali Akbar Saboury; Elham Rezaee; Sayyed Abbas Tabatabai
Journal:  Eur Biophys J       Date:  2016-12-07       Impact factor: 1.733

Review 5.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Authors:  Christophe Morisseau; Bruce D Hammock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

6.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

7.  Protostane-type triterpenoids as natural soluble epoxide hydrolase inhibitors: Inhibition potentials and molecular dynamics.

Authors:  Cheng-Peng Sun; Juan Zhang; Wen-Yu Zhao; Jing Yi; Jian-Kun Yan; Ya-Li Wang; Christophe Morisseau; Zhong-Bo Liu; Bruce D Hammock; Xiao-Chi Ma
Journal:  Bioorg Chem       Date:  2020-01-29       Impact factor: 5.275

8.  Occurrence of urea-based soluble epoxide hydrolase inhibitors from the plants in the order Brassicales.

Authors:  Seiya Kitamura; Christophe Morisseau; Todd R Harris; Bora Inceoglu; Bruce D Hammock
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

Review 9.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.